Swiss Group for Clinical Cancer Research (SAKK)
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Rordorf T, Hassan A, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B, Swiss Group for Clinical Cancer Research (SAKK). Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup. Breast 2014; 23:511-25.
Jun 27, 2014Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
Jun 27, 2014Breast 2014; 23:511-25
Rordorf Tamara, Hassan Azza Adel, Azim Hamdy, Alexandru Eniu, Er Ozlem, Gokmen Erhan, Güral Zeynep, Mardiak Jozef, Minchev Velko, Peintinger Florentia, Szendroi Miklos, Takac Itzok, Tesarova Petra, Vorobiof Daniel, Vrbanec Damir, Yildiz Ramazan, Yücel Serap, Zekri Jamal, Oyan Basak, Swiss Group for Clinical Cancer Research (SAKK)
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013; 64:150-8.
Apr 6, 2013Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
Apr 6, 2013Eur Urol 2013; 64:150-8
Templeton Arnoud, Schiess Ralph, Wild Peter J, Rüschoff Jan H, Thalmann George, Dietrich Pierre-Yves, Aebersold Ruedi, Klingbiel Dirk, Gillessen Sommer Silke, Müller Beat, Winterhalder Ralph, Stenner Frank, Dutoit Valérie, Cathomas Richard, Rothermundt Christian, Bärtschi Daniela, Dröge Cornelia, Gautschi Oliver, Borner Markus, Fechter Eva, Swiss Group for Clinical Cancer Research (SAKK)
Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
Schoenewolf N, von Moos R, Schraml P, Gillessen Sommer S, Ochsenbein A, Simcock M, Moch H, Mihic-Probst D, Dummer R, Swiss Group for Clinical Cancer Research (SAKK). Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case Rep Oncol 2012; 5:280-9.
Jun 5, 2012Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
Jun 5, 2012Case Rep Oncol 2012; 5:280-9
Schoenewolf Nicola L, von Moos Roger, Schraml Peter, Gillessen Sommer Silke, Ochsenbein Adrian, Simcock Mathew, Moch Holger, Mihic-Probst Daniela, Dummer Reinhard, Swiss Group for Clinical Cancer Research (SAKK)
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Köberle D, Thürlimann B, Pilop C, Crowe S, Öhlschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer 2011; 18:257-64.
Mar 9, 2011Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Mar 9, 2011Endocr Relat Cancer 2011; 18:257-64
Köberle Dieter, Thürlimann Beat, Pilop C, Crowe S, Öhlschlegel Christian, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober J, Spirig C, Lerch S, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol 2010; 22:80-5.
Jul 1, 2010Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Jul 1, 2010Ann Oncol 2010; 22:80-5
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober Jens, Spirig C, Lerch S, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Ruhstaller T, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle D, Balmermajno S, Pestalozzi B, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J, Widmer L, Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8.
Sep 1, 2009Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Sep 1, 2009Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8
Ruhstaller Thomas, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle Dieter, Balmermajno S, Pestalozzi B C, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J C, Widmer L, Swiss Group for Clinical Cancer Research (SAKK)
Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95
Zenhäusern R, Tobler A, Leoncini L, Kovacsovic T, Bargetzi M, Hess U, Gratwohl A, Meyer-Monard S, Solenthaler M, Rufibach K, von Rohr A, Swiss Group for Clinical Cancer Research (SAKK). Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95. Leukemia & lymphoma 2009; 50:133-6.
Jan 1, 2009Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95
Jan 1, 2009Leukemia & lymphoma 2009; 50:133-6
Zenhäusern Reinhard, Tobler Andreas, Leoncini Leda, Kovacsovic Tibor, Bargetzi Mario J, Hess Urs, Gratwohl Alois, Meyer-Monard Sandrine, Solenthaler Max, Rufibach Kaspar, von Rohr Albert, Swiss Group for Clinical Cancer Research (SAKK)
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
Leyvraz S, Pestalozzi B, Dietrich D, Cerny T, Wernli M, Sessa C, Fey M, Christinat A, Honegger H, Guillou L, Herrmann R, Swiss Group for Clinical Cancer Research (SAKK). Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. British journal of cancer 2006; 95:1342-7.
Nov 20, 2006Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
Nov 20, 2006British journal of cancer 2006; 95:1342-7
Leyvraz S, Pestalozzi B, Dietrich D, Cerny Thomas, Wernli M, Sessa C, Fey M F, Christinat A, Honegger H P, Guillou L, Herrmann R, Swiss Group for Clinical Cancer Research (SAKK)
Diagnosis of Burkitt lymphoma in due time: a practical approach
Cogliatti S, Novak U, Henz S, Schmid U, Möller P, Barth T, Swiss Group for Clinical Cancer Research (SAKK). Diagnosis of Burkitt lymphoma in due time: a practical approach. British journal of haematology 2006; 134:294-301.
Aug 1, 2006Diagnosis of Burkitt lymphoma in due time: a practical approach
Aug 1, 2006British journal of haematology 2006; 134:294-301
Cogliatti Sergio B., Novak Urban, Henz Samuel, Schmid Ulrico, Möller Peter, Barth Thomas F E, Swiss Group for Clinical Cancer Research (SAKK)
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
Betticher D, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H, Stahel R, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. British journal of cancer 2006; 94:1099-106.
Apr 24, 2006Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
Apr 24, 2006British journal of cancer 2006; 94:1099-106
Betticher D C, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny Thomas, Ris H-B, Stahel R, Spiliopoulos A, Roth A D, Hsu Schmitz S-F, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R A, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK)
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sabbioni M, Hürny C, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Gertsch M, Schmitz S, Siegrist H, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?. Breast Cancer Res Treat 2004; 87:75-86.
Sep 1, 2004Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sep 1, 2004Breast Cancer Res Treat 2004; 87:75-86
Sabbioni Marzio E E, Hürny Christoph, Goldhirsch Aron, Herrmann Richard, Perey Lucien, Bonnefoi Hervé, Thürlimann Beat, Gertsch Monica Castiglione, Schmitz Shu-Fang Hsu, Siegrist Hans-Peter, Bernhard Jürg, Swiss Group for Clinical Cancer Research (SAKK)
Re: Playing the old piano: another tune for endocrine therapy
Köberle D, Perey L, Thürlimann B, Swiss Group for Clinical Cancer Research (SAKK). Re: Playing the old piano: another tune for endocrine therapy. Journal of the National Cancer Institute 2004; 96:555-6; author reply 556-7.
Apr 7, 2004Re: Playing the old piano: another tune for endocrine therapy
Apr 7, 2004Journal of the National Cancer Institute 2004; 96:555-6; author reply 556-7
Köberle Dieter, Perey Lucien, Thürlimann Beat, Swiss Group for Clinical Cancer Research (SAKK)
Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner K, Borner M, Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21.
Aug 1, 2003Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Aug 1, 2003Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21
Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann Beat, Goldhirsch A, Brunner K W, Borner M M, Swiss Group for Clinical Cancer Research (SAKK)